25 May 2013
Keywords: duska, files, ph, iii, atpace, protocol, fda
Article | 04 August 2008
California, USA-headquartered Duska Therapeutics has submitted for comment a synopsis of a proposed Phase III clinical study for its lead
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
4 August 2008
24 May 2013
© 2013 thepharmaletter.com